8-K: PepGen Receives Clinical Hold from FDA for Duchenne Muscular Dystrophy Trial

PepGen has announced a clinical hold by the FDA on its Investigational New Drug application for the CONNECT2-EDO51 trial for Duchenne muscular dystrophy.

Summary

• PepGen Inc. has received a clinical hold notice from the U.S. Food and Drug Administration (FDA) regarding its Investigational New Drug (IND) application to initiate the CONNECT2-EDO51 clinical trial.
• The CONNECT2 trial is a Phase 2 multinational, double-blind, placebo-controlled study of PGN-EDO51 in patients with Duchenne muscular dystrophy (DMD).
• The FDA will provide an official clinical hold letter to PepGen within 30 days.
• PepGen intends to work closely with the FDA to address their questions regarding the application.
• The company's CONNECT1-EDO51 study of PGN-EDO51 in Canada is ongoing, with the 10 mg/kg dose cohort fully enrolled.
• PGN-EDO51 is designed to skip exon 51 of the dystrophin transcript, a target for approximately 13% of DMD patients.

Sentiment

Score: 3

Explanation: The clinical hold is a significant negative event, impacting the company's timeline and potentially its valuation. While the company is working to address the issues, the uncertainty and delay warrant a low sentiment score.

Positives

• PepGen is actively working to address the FDA's concerns regarding the CONNECT2-EDO51 trial.
• The CONNECT1-EDO51 study is progressing as planned in Canada, with the 10 mg/kg cohort fully enrolled.
• PGN-EDO51 has received Orphan Drug and Rare Pediatric Disease Designations from the FDA.
• PepGen's EDO platform is based on over a decade of research and development.

Negatives

• The FDA has issued a clinical hold on the IND application for the CONNECT2-EDO51 trial, which will delay the start of the trial.
• The FDA has not yet provided specific reasons for the clinical hold, which will be detailed in a letter within 30 days.

Risks

• There is a risk that the FDA's concerns may not be easily addressed, potentially delaying or preventing the CONNECT2-EDO51 trial.
• The clinical hold could impact the company's timeline and financial resources.
• There is no guarantee that PGN-EDO51 will successfully complete clinical development or gain regulatory approval.
• The company is dependent on third parties for manufacturing, research, and testing.

Future Outlook

PepGen intends to work closely with the FDA to address their questions on the application to initiate CONNECT2 as expeditiously as possible. The company will continue to advance PGN-EDO51 in the CONNECT1-EDO51 study.

Management Comments

• Paul Streck, MD, MBA, Head of R&D of PepGen, stated that they intend to work closely with the FDA to address their questions on the application to initiate CONNECT2 as expeditiously as possible.

Industry Context

The clinical hold highlights the regulatory challenges in developing new therapies for rare diseases like Duchenne muscular dystrophy. It is not uncommon for clinical trials to face holds or delays, especially in novel therapeutic areas.

Comparison to Industry Standards

• Clinical holds are not uncommon in the pharmaceutical industry, particularly for novel therapies.
• Companies like Sarepta Therapeutics and BioMarin have also faced regulatory hurdles in the development of DMD treatments.
• The 30-day timeframe for the FDA to provide a detailed letter is standard practice.
• The focus on exon skipping is a common approach in DMD treatment development, with several companies pursuing similar strategies.

Stakeholder Impact

• Shareholders may react negatively to the clinical hold announcement.
• Patients and families affected by DMD may experience disappointment due to the delay in the trial.
• Employees may face uncertainty regarding the future of the CONNECT2-EDO51 program.

Next Steps

• PepGen will work with the FDA to address the questions regarding the IND application for CONNECT2-EDO51.
• The FDA will provide an official clinical hold letter within 30 days.
• PepGen will continue to advance PGN-EDO51 in the ongoing CONNECT1-EDO51 study.

Key Dates

Keywords

Clinical Hold, FDA, Duchenne Muscular Dystrophy, PGN-EDO51, CONNECT2-EDO51, CONNECT1-EDO51, Oligonucleotide Therapy, Exon Skipping, Rare Pediatric Disease, Biotechnology